Trial Profile
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Bevacizumab; Erlotinib; Everolimus; Fulvestrant; Sorafenib
- Indications Solid tumours
- Focus Adverse reactions
- 20 Jan 2021 Status changed from active, no longer recruiting to completed.
- 10 Jan 2020 Planned End Date changed from 1 Sep 2020 to 30 Sep 2020.
- 10 Jan 2020 Planned primary completion date changed from 1 Sep 2019 to 30 Sep 2020.